In contrast to thrombotic diseases where blocking PAI-1 needs to be rapidly but also transiently achieved, targeting PAI-1 in cancer requires the chronic administration of an inhibitor and thus a much more favorable pharmacokinetic profile where effective concentrations can be achieved for longer periods of time. This evidence concerns the gene SERPINE1 and thrombotic disease.